TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,313.20▼ 0.75%TCS₹2,298.00▲ 2.08%HDFCBANK₹725.05▼ 6.76%ICICIBANK₹1,411.90▼ 3.31%INFY₹1,130.00▲ 3.95%HINDUNILVR₹2,028.00▼ 5.22%ITC₹271.65▼ 3.91%SBIN₹1,048.00▼ 1.13%BHARTIARTL₹1,941.70▼ 0.34%KOTAKBANK₹397.35▲ 4.00%LT₹4,081.00▲ 6.31%AXISBANK₹1,251.00▼ 0.40%ASIANPAINT₹2,625.20▼ 2.50%MARUTI₹13,809.00▲ 2.18%AAPL$317.61▼ 2.75%MSFT$481.14▲ 19.60%GOOGL$341.22▼ 3.06%AMZN$261.20▲ 4.48%NVDA$218.03▲ 7.26%META$544.51▼ 15.69%TSLA$341.10▼ 7.70%BRK-B$499.37▲ 1.65%JPM$357.57▲ 5.52%V$368.75▲ 2.27%
RELIANCE₹1,313.20▼ 0.75%TCS₹2,298.00▲ 2.08%HDFCBANK₹725.05▼ 6.76%ICICIBANK₹1,411.90▼ 3.31%INFY₹1,130.00▲ 3.95%HINDUNILVR₹2,028.00▼ 5.22%ITC₹271.65▼ 3.91%SBIN₹1,048.00▼ 1.13%BHARTIARTL₹1,941.70▼ 0.34%KOTAKBANK₹397.35▲ 4.00%LT₹4,081.00▲ 6.31%AXISBANK₹1,251.00▼ 0.40%ASIANPAINT₹2,625.20▼ 2.50%MARUTI₹13,809.00▲ 2.18%AAPL$317.61▼ 2.75%MSFT$481.14▲ 19.60%GOOGL$341.22▼ 3.06%AMZN$261.20▲ 4.48%NVDA$218.03▲ 7.26%META$544.51▼ 15.69%TSLA$341.10▼ 7.70%BRK-B$499.37▲ 1.65%JPM$357.57▲ 5.52%V$368.75▲ 2.27%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ASND

Ascendis Pharma A/S - Ordinary Share

NASDAQ
$256.83
▲ $5.07 (+2.0%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Aug 2026
H $282.15L $203.80+15.6%
$282.15$266.48$250.81$235.14$219.47$203.8$256.83
RSI (14)
Intraday · 15-minBuy+20RSI 51UptrendMACD Bearishfor day-trading context — not advice

Technical signal

Strong buy+65
RSI (14)55
oversold 30overbought 70
Trend
Uptrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
above
vs 50-day
above
vs 200-day
above
Support
$239.56
Resistance
$261.61
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2025-11-13 → 2026-08-20

Strategy return
-14.9%
Buy & hold
+24.4%
Trades
10
Win rate
20%

$100,000.00 invested would be worth $85,151.93 (-14.8%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Ascendis Pharma A/S· Biotechnology

source: yahoo

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Sector
Healthcare
Industry
Biotechnology
Employees
1,189
Headquarters
Hellerup, Denmark
ascendispharma.com ↗

Fundamentals

source: yahoo
Market cap
$16.85B
P/E
19.8
P/B
10.1
EPS
$12.97
Div yield
—
Profit margin
70.8%
ROE
118.8%
Debt / Equity
0.31
Beta
—
52-week range
$186.05 – $282.15
52-week low · $186.0574% of rangehigh · $282.15

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive2↑ · 0↓ · 6–
  • Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript— Neutral
    Motley Fool · 20 Aug 2026
  • Is Ascendis Pharma (ASND) Priced Too Richly After Recent Progress?— Neutral
    Simply Wall St. · 20 Aug 2026
  • Ascendis Pharma (ASND) Reports Earnings And Trial Updates, Is It Fully Priced?— Neutral
    Simply Wall St. · 20 Aug 2026
  • BMO Capital Initiates Ascendis Pharma at Outperform

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

▲ Positive
MT Newswires · 19 Aug 2026
  • Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients— Neutral
    GlobeNewswire · 18 Aug 2026
  • Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says▲ Positive
    MT Newswires · 14 Aug 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.